JP2014524437A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524437A5
JP2014524437A5 JP2014525931A JP2014525931A JP2014524437A5 JP 2014524437 A5 JP2014524437 A5 JP 2014524437A5 JP 2014525931 A JP2014525931 A JP 2014525931A JP 2014525931 A JP2014525931 A JP 2014525931A JP 2014524437 A5 JP2014524437 A5 JP 2014524437A5
Authority
JP
Japan
Prior art keywords
disease
degenerative neurological
nerve
group
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014525931A
Other languages
English (en)
Japanese (ja)
Other versions
JP5872041B2 (ja
JP2014524437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from KR1020120088778A external-priority patent/KR101405437B1/ko
Publication of JP2014524437A publication Critical patent/JP2014524437A/ja
Publication of JP2014524437A5 publication Critical patent/JP2014524437A5/ja
Application granted granted Critical
Publication of JP5872041B2 publication Critical patent/JP5872041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014525931A 2011-08-16 2012-08-14 幹細胞由来微小胞を含む神経生成促進用組成物 Active JP5872041B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0081147 2011-08-16
KR20110081147 2011-08-16
KR1020120088778A KR101405437B1 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
PCT/KR2012/006478 WO2013025042A2 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
KR10-2012-0088778 2012-08-14

Publications (3)

Publication Number Publication Date
JP2014524437A JP2014524437A (ja) 2014-09-22
JP2014524437A5 true JP2014524437A5 (https=) 2015-07-16
JP5872041B2 JP5872041B2 (ja) 2016-03-01

Family

ID=47897528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525931A Active JP5872041B2 (ja) 2011-08-16 2012-08-14 幹細胞由来微小胞を含む神経生成促進用組成物

Country Status (5)

Country Link
US (2) US20150045298A1 (https=)
EP (1) EP2745840B1 (https=)
JP (1) JP5872041B2 (https=)
KR (1) KR101405437B1 (https=)
WO (1) WO2013025042A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
EP2838995A4 (en) * 2012-04-16 2016-01-06 Univ California EYE THERAPEUTICS WITH MICROVESICLES FROM EMBRYONAL STEM CELLS
US10072247B2 (en) * 2012-10-05 2018-09-11 Samsung Life Public Welfare Foundation Composition comprising ischemic serum for promoting activation of stem cell and method for promoting activation of stem cell
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
US10167448B2 (en) 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
CN105520911A (zh) * 2014-09-30 2016-04-27 重庆润泽医药有限公司 一种奥拉西坦脂质微泡及其制备方法
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
SG11201803145RA (en) * 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
WO2017152035A1 (en) * 2016-03-03 2017-09-08 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EP3308795A1 (en) * 2016-10-12 2018-04-18 Unicyte EV AG A composition of extracellular vesicles (evs) and medical uses thereof
EP3568143B1 (en) * 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
KR102184722B1 (ko) * 2018-01-31 2020-12-01 서울대학교산학협력단 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
EP3827076A1 (en) 2018-07-26 2021-06-02 Uniwersytet Jagiellonski In vivo delivery system of the genome dna modifying enzymes and the use thereof
US11351119B2 (en) 2018-10-25 2022-06-07 Samsung Life Public Welfare Foundation Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy
KR102320800B1 (ko) * 2018-10-25 2021-11-02 사회복지법인 삼성생명공익재단 효능이 증진된 줄기세포 유래 미세소포, 이의 용도 및 효능강화 방법
CN114306238A (zh) * 2020-09-29 2022-04-12 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
KR20230047936A (ko) * 2021-10-01 2023-04-10 주식회사 입셀 유도만능줄기세포 배양 배지 유래 성분을 포함하는 조성물 내지 이의 용도
WO2024090922A1 (ko) * 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物
KR20260010585A (ko) * 2024-07-12 2026-01-21 (주) 테라베스트 조혈모세포 또는 자연살해세포 유래의 세포외 소포체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020815A1 (en) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
US20100233216A1 (en) 2007-10-15 2010-09-16 Vincenzo Cantaluppi Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
CN101854941B (zh) * 2007-10-29 2013-03-27 弗雷森纽斯医疗护理德国有限责任公司 衍生自干细胞的微泡(MVs)用于制备用于受损或损伤组织或器官的内皮/上皮再生的药物的用途、以及相关体外和体内方法
AU2009203638C1 (en) * 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
EP2254586B1 (en) * 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
EP2376069B1 (en) * 2008-12-19 2019-03-20 Cellerix, S.A. Microparticles comprising adipose stem cells
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
WO2011053257A2 (en) * 2009-11-02 2011-05-05 Agency For Science, Technology And Research (A*Star) Methods of monitoring cellular states

Similar Documents

Publication Publication Date Title
JP2014524437A5 (https=)
BR112015023267A8 (pt) composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido
JOP20210231A1 (ar) مركبات ترابطية مستهدفة كمركبات علاجية
UA113641C2 (xx) Інгібітори бета-секретази
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JOP20200050A1 (ar) عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
MX2023006105A (es) Ligandos de direccion.
EA201790817A1 (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера
WO2015164750A3 (en) Compositions and methods to treating hemoglobinopathies
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
TW201613932A (en) Organic compounds
RU2018124487A (ru) Лечение внутрипеченочного холестаза и родственных заболеваний печени
MA44948A1 (fr) Inhibiteurs de bace 1
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EP2796142A4 (en) PHARMACEUTICAL COMPOSITION WITH DEATH CELLS FROM LACTOBACILLUS ACIDOPHILUS LB STRAIN FOR THE TREATMENT OR PREVENTION OF ALLERGIES
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
WO2016183593A3 (en) Prenatal therapy